Comparative Pharmacology
Head-to-head clinical analysis: ARISTOCORT versus DEXACEN 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOCORT versus DEXACEN 4.
ARISTOCORT vs DEXACEN-4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; modulates gene expression and immune cell activity.
Dexamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to increased transcription of anti-inflammatory proteins and suppression of pro-inflammatory mediators.
Intramuscular: 40-80 mg every 2-4 weeks; Intra-articular: 5-40 mg depending on joint size; Intralesional: 2.5-25 mg; Oral: 4-12 mg/day divided every 6-12 hours.
Dexamethasone 4 mg orally or intravenously every 6-8 hours; typical adult dose is 4-20 mg/day in divided doses, depending on condition.
None Documented
None Documented
Plasma: 1-2 hours (triamcinolone); tissue half-life 18-36 hours due to receptor binding and slow release from tissues.
3-4 hours; prolonged to 6-8 hours in renal impairment (CrCl <30 mL/min)
Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal elimination minor.
Renal: 65-80% as unchanged drug; Biliary: 10-15% as metabolites; Fecal: <5%
Category C
Category C
Corticosteroid
Corticosteroid